CB4500 is Canopus BioPharma’s HIV peptide vaccine candidate which has the capacity to generate antibodies that will inhibit the ability of the HIV virus to down regulate an infected patient’s immune system and prevent the development of Acquired Immune Deficiency Syndrome (AIDS).
Future studies will investigate if vaccination with CB4500 peptides protect the immune system and reduce HIV viral load in a mouse model of HIV. In addition, Canopus will initiate a primate SIV model to confirm protection to SIV infection, either prophylactic or therapeutically, using the CB4500 peptide vaccine.
Patents for this vaccine are currently being processed.
CB1922 is a prescription synthetic steroidal lactone with properties compatible with competitive mineral corticoid antagonism, which are used in the treatment of oedematous states, primary hyper aldosteronism and essential hypertension.
The active ingredient in CB1922, steroidal lactone is well known in the medical field for its indication in the cardiovascular area, with very well documented pharmacokinetic profile and well known side effects.
During the course of Canopus BioPharma's research it was discovered that certain proteins on the coat of the HIV virus mimics in binding characteristics the steroid molecule aldosterone. The virus uses this steroid mimic peptide on its surface to bind a mineralocorticoid steroid type receptor and cause electrolyte changes in the infected cell.
Canopus BioPharma screened a selection of prescription aldosterone agonists and antagonists and discovered that certain examples of these molecules significantly inhibited HIV replication. CB1922 significantly inhibits HIV viral replication, particularly in macrophages.
CB1922 and related formulations of aldosterone antagonists will offer the physician and HIV+ patients a new avenue to obstruct HIV viral replication both as a mono-therapy and in association with conventional antivirals to augment their effectiveness. Thus CB1922 offers the patient and physician a new therapeutic approach to inhibiting the HIV virus and also inhibiting the decline of the immune system, utilizing a drug family with over 30 years of patient administration history.
Canopus has international patents pending relating to the use of CB1922 to treat HIV infections. This application has been entered into the national phase.